Melezínek I - Search Results

1

Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis.

Paz-Ares L, Soulières D, Melezínek I, Moecks J, Keil L, Mok T, Rosell R, Klughammer B. Paz-Ares L, et al. Among authors: melezinek i. J Cell Mol Med. 2010 Jan;14(1-2):51-69. doi: 10.1111/j.1582-4934.2009.00991.x. Epub 2009 Dec 8. J Cell Mol Med. 2010. PMID: 20015198 Free PMC article. Review.

2

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E, Esteban E, Molinier O, Brugger W, Melezínek I, Klingelschmitt G, Klughammer B, Giaccone G; SATURN investigators. Cappuzzo F, et al. Among authors: melezinek i. Lancet Oncol. 2010 Jun;11(6):521-9. doi: 10.1016/S1470-2045(10)70112-1. Epub 2010 May 20. Lancet Oncol. 2010. PMID: 20493771 Clinical Trial.

3

Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study.

Ranson M, Reck M, Anthoney A, Hanauske AR, Dean E, Melezinek I, Klingelschmitt G, Kletzl H, Blatter J, Twelves C. Ranson M, et al. Among authors: melezinek i. Ann Oncol. 2010 Nov;21(11):2233-2239. doi: 10.1093/annonc/mdq246. Epub 2010 May 5. Ann Oncol. 2010. PMID: 20444843 Free article. Clinical Trial.

4

Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.

Van Cutsem E, Lenz HJ, Köhne CH, Heinemann V, Tejpar S, Melezínek I, Beier F, Stroh C, Rougier P, van Krieken JH, Ciardiello F. Van Cutsem E, et al. Among authors: melezinek i. J Clin Oncol. 2015 Mar 1;33(7):692-700. doi: 10.1200/JCO.2014.59.4812. Epub 2015 Jan 20. J Clin Oncol. 2015. PMID: 25605843 Free article. Clinical Trial.

5

Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup.

Iversen P, Tyrrell CJ, Kaisary AV, Anderson JB, Van Poppel H, Tammela TL, Chamberlain M, Carroll K, Melezinek I. Iversen P, et al. Among authors: melezinek i. J Urol. 2000 Nov;164(5):1579-82. J Urol. 2000. PMID: 11025708

6

The non-steroidal antiandrogen, bicalutamide ('Casodex'), may preserve bone mineral density as compared with castration: results of a preliminary study.

Tyrrell CJ, Blake GM, Iversen P, Kaisary AV, Melezinek I. Tyrrell CJ, et al. Among authors: melezinek i. World J Urol. 2003 May;21(1):37-42. doi: 10.1007/s00345-003-0322-7. Epub 2003 Mar 22. World J Urol. 2003. PMID: 12756493

7

Nonsteroidal antiandrogens: a therapeutic option for patients with advanced prostate cancer who wish to retain sexual interest and function.

Iversen P, Melezinek I, Schmidt A. Iversen P, et al. Among authors: melezinek i. BJU Int. 2001 Jan;87(1):47-56. doi: 10.1046/j.1464-410x.2001.00988.x. BJU Int. 2001. PMID: 11121992 Review. No abstract available.

8

The role of prostate specific antigen measurement in the detection and management of prostate cancer.

Nash AF, Melezinek I. Nash AF, et al. Among authors: melezinek i. Endocr Relat Cancer. 2000 Mar;7(1):37-51. doi: 10.1677/erc.0.0070037. Endocr Relat Cancer. 2000. PMID: 10808195 Review.

9

Tumour tissue is a source of gamma-glutamyl transpeptidase sialoform in the sera of melanoma-bearing mice.

Melezínek I, Borovanský J, Elleder M, Bubnová E. Melezínek I, et al. Melanoma Res. 1998 Feb;8(1):39-45. Melanoma Res. 1998. PMID: 9508375

10

[Gamma-glutamyltranspeptidase as a tumor marker].

Melezínek I. Melezínek I. Cesk Fysiol. 1991;40(6):545-60. Cesk Fysiol. 1991. PMID: 1687520 Review. Czech. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

12 results

Search Page

Filters